These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 27009216)

  • 1. Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth.
    Huang J; Hu W; Hu L; Previs RA; Dalton HJ; Yang XY; Sun Y; McGuire M; Rupaimoole R; Nagaraja AS; Kang Y; Liu T; Nick AM; Jennings NB; Coleman RL; Jaffe RB; Sood AK
    Mol Cancer Ther; 2016 Jun; 15(6):1344-52. PubMed ID: 27009216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dll4 Blockade in Stromal Cells Mediates Antitumor Effects in Preclinical Models of Ovarian Cancer.
    Kuhnert F; Chen G; Coetzee S; Thambi N; Hickey C; Shan J; Kovalenko P; Noguera-Troise I; Smith E; Fairhurst J; Andreev J; Kirshner JR; Papadopoulos N; Thurston G
    Cancer Res; 2015 Oct; 75(19):4086-96. PubMed ID: 26377940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer.
    Kim DH; Lee S; Kang HG; Park HW; Lee HW; Kim D; Yoem DH; Ahn JH; Ha E; You WK; Lee SH; Kim SJ; Chun KH
    BMB Rep; 2020 Nov; 53(10):533-538. PubMed ID: 32580836
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-165, a Dual Variable Domain Immunoglobulin (DVD-Ig) Targeting DLL4 and VEGF, Demonstrates Superior Efficacy and Favorable Safety Profiles in Preclinical Models.
    Li Y; Hickson JA; Ambrosi DJ; Haasch DL; Foster-Duke KD; Eaton LJ; DiGiammarino EL; Panchal SC; Jiang F; Mudd SR; Zhang C; Akella SS; Gao W; Ralston SL; Naumovski L; Gu J; Morgan-Lappe SE
    Mol Cancer Ther; 2018 May; 17(5):1039-1050. PubMed ID: 29592882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo.
    Li JL; Sainson RC; Oon CE; Turley H; Leek R; Sheldon H; Bridges E; Shi W; Snell C; Bowden ET; Wu H; Chowdhury PS; Russell AJ; Montgomery CP; Poulsom R; Harris AL
    Cancer Res; 2011 Sep; 71(18):6073-83. PubMed ID: 21803743
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the insulin growth factor and the vascular endothelial growth factor pathways in ovarian cancer.
    Shao M; Hollar S; Chambliss D; Schmitt J; Emerson R; Chelladurai B; Perkins S; Ivan M; Matei D
    Mol Cancer Ther; 2012 Jul; 11(7):1576-86. PubMed ID: 22700681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential antitumor activity of aflibercept and bevacizumab in patient-derived xenograft models of colorectal cancer.
    Chiron M; Bagley RG; Pollard J; Mankoo PK; Henry C; Vincent L; Geslin C; Baltes N; Bergstrom DA
    Mol Cancer Ther; 2014 Jun; 13(6):1636-44. PubMed ID: 24688047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological roles of the Delta family Notch ligand Dll4 in tumor and endothelial cells in ovarian cancer.
    Hu W; Lu C; Dong HH; Huang J; Shen DY; Stone RL; Nick AM; Shahzad MM; Mora E; Jennings NB; Lee SJ; Roh JW; Matsuo K; Nishimura M; Goodman BW; Jaffe RB; Langley RR; Deavers MT; Lopez-Berestein G; Coleman RL; Sood AK
    Cancer Res; 2011 Sep; 71(18):6030-9. PubMed ID: 21795478
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of aflibercept in in vitro and in vivo models of retinoblastoma.
    Kim DY; Choi JA; Koh JY; Yoon YH
    J Exp Clin Cancer Res; 2016 Nov; 35(1):171. PubMed ID: 27814771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination of Dll4/Notch and Ephrin-B2/EphB4 targeted therapy is highly effective in disrupting tumor angiogenesis.
    Djokovic D; Trindade A; Gigante J; Badenes M; Silva L; Liu R; Li X; Gong M; Krasnoperov V; Gill PS; Duarte A
    BMC Cancer; 2010 Nov; 10():641. PubMed ID: 21092311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined blockade of HER2 and VEGF exerts greater growth inhibition of HER2-overexpressing gastric cancer xenografts than individual blockade.
    Singh R; Kim WJ; Kim PH; Hong HJ
    Exp Mol Med; 2013 Nov; 45(11):e52. PubMed ID: 24176949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer.
    Merritt WM; Nick AM; Carroll AR; Lu C; Matsuo K; Dumble M; Jennings N; Zhang S; Lin YG; Spannuth WA; Kamat AA; Stone RL; Shahzad MM; Coleman RL; Kumar R; Sood AK
    Mol Cancer Ther; 2010 Apr; 9(4):985-95. PubMed ID: 20371710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-MUC1 monoclonal antibody (C595) and docetaxel markedly reduce tumor burden and ascites, and prolong survival in an in vivo ovarian cancer model.
    Wang L; Chen H; Pourgholami MH; Beretov J; Hao J; Chao H; Perkins AC; Kearsley JH; Li Y
    PLoS One; 2011; 6(9):e24405. PubMed ID: 21931707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo.
    Li JL; Sainson RC; Shi W; Leek R; Harrington LS; Preusser M; Biswas S; Turley H; Heikamp E; Hainfellner JA; Harris AL
    Cancer Res; 2007 Dec; 67(23):11244-53. PubMed ID: 18056450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The expression of VEGF and Dll4/Notch pathway molecules in ovarian cancer.
    Wang H; Huang X; Zhang J; Shao N; Chen LO; Ma D; Ji C
    Clin Chim Acta; 2014 Sep; 436():243-8. PubMed ID: 24949865
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of ephrinB2 in nonproductive angiogenesis induced by Delta-like 4 blockade.
    Yamanda S; Ebihara S; Asada M; Okazaki T; Niu K; Ebihara T; Koyanagi A; Yamaguchi N; Yagita H; Arai H
    Blood; 2009 Apr; 113(15):3631-9. PubMed ID: 19218547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the notch ligand JAGGED1 in both tumor cells and stroma in ovarian cancer.
    Steg AD; Katre AA; Goodman B; Han HD; Nick AM; Stone RL; Coleman RL; Alvarez RD; Lopez-Berestein G; Sood AK; Landen CN
    Clin Cancer Res; 2011 Sep; 17(17):5674-85. PubMed ID: 21753153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MMGZ01, an anti-DLL4 monoclonal antibody, promotes nonfunctional vessels and inhibits breast tumor growth.
    Xu Z; Wang Z; Jia X; Wang L; Chen Z; Wang S; Wang M; Zhang J; Wu M
    Cancer Lett; 2016 Mar; 372(1):118-27. PubMed ID: 26739060
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination DLL4 with Jagged1-siRNA can enhance inhibition of the proliferation and invasiveness activity of human gastric carcinoma by Notch1/VEGF pathway.
    Sun HW; Wu C; Tan HY; Wang QS
    Hepatogastroenterology; 2012 May; 59(115):924-9. PubMed ID: 22020917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.